Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Oct 22;15:1488853. doi: 10.3389/fimmu.2024.1488853

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Kuang, Yan, Li, Lin, Li, Zhang, Luo and Yin

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Assessment of the correlation between VEGF(R) inhibitor-associated hypertension adverse effects and key signaling pathways. (A) Rates of reporting (ROR) of VEGF(R) inhibitor-associated hypertensive adverse reactions in 29 cancer types; tumor types with fewer than 5 cases were not included in the analysis. (B) Correlation analysis of negative feedback regulation of the MAPK pathway with ssGSEA enrichment scores of hypertensive adverse reactions. (C) Correlation analysis of negative regulation of triglyceride metabolic processes with ssGSEA enrichment scores of hypertensive adverse reactions. (D) Correlation analysis of the regulation of inositol 1,4,5-trisphosphate-sensitive calcium release channel activity with ssGSEA enrichment scores for adverse reactions to hypertension. (E) Correlation analysis of nitric oxide eNOS-activated and regulated metabolism with ssGSEA enrichment scores for adverse reactions to hypertension. Cancer types included: PRAD, prostate adenocarcinoma; OV, ovarian cancer; COAD, colon adenocarcinoma; THCA, thyroid cancer; CHOL, cholangiocarcinoma; KIRP, renal pelvis adenocarcinoma; LUAD, lung adenocarcinoma; LIHC, hepatocellular carcinoma; LAML, acute myeloid leukemia; PAAD, pancreatic adenocarcinoma; STAD, gastric adenocarcinoma; MESO, mesothelioma; READ, rectal adenocarcinoma; ESCA, esophageal cancer; BRCA, breast invasive carcinoma; KIRC, kidney clear cell carcinoma; BLCA, bladder urothelial carcinoma; UCS, uterine sarcoma; SARC, soft tissue sarcoma; CRC, colorectal carcinoma; DLBC, diffuse large B-cell lymphoma; LUSC, lung squamous cell carcinoma; ACC, adrenal cortical cancer; GBM, glioblastoma; CESC, cervical squamous cell carcinoma and cervical adenocarcinoma; NSCLC, non-small cell lung cancer; SKCM, skin melanoma; UCEC, endometrial carcinoma; HNSC, head and neck squamous cell carcinoma.